ENVB - Earnings announcements

EB-003 Development Highlights: Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial Reported preclinical data demonstrating that EB-003 consistently exhibited a non-hallucinogenic profile in a highly sensitive GloSensor™ assay, complementing previously reported BRET assay findings Announced promising results from preclinical in vitro experiments indicating no photoreactive potential for EB-003, further derisking its continued development as a potential treatment of neuropsychiatric disorders Initiated genotoxicity studies to evaluate the potential f

Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe